MARKET

SYN

SYN

SYNTHETIC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5525
+0.0101
+1.86%
After Hours: 0.5800 +0.0275 +4.98% 18:42 01/24 EST
OPEN
0.5510
PREV CLOSE
0.5424
HIGH
0.5800
LOW
0.5509
VOLUME
323.09K
TURNOVER
--
52 WEEK HIGH
0.8499
52 WEEK LOW
0.3650
MARKET CAP
9.29M
P/E (TTM)
-0.2916
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SYN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SYN News

  • Synovus slips 1.5% as Q4 EPS disappoints
  • Seeking Alpha - Article.1d ago
  • Synthetic Bio up 9% on advancement of co-lead candidate
  • seekingalpha.01/07 22:13
  • Synthetic Biologics Receives FDA Guidance At Type C Meeting For SYN-004 Phase 1b/2a Clinical Trial In Allogeneic HCT Recipients
  • Benzinga.01/07 12:08
  • Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
  • PR Newswire.01/07 12:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About SYN

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).
More

Webull offers Synthetic Biologics Inc (SYN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.